Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | SVP Controller | February 09, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,272 |
Ending reported balance
After 2026-02-09 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2026-02-09 · Exercise / conversion · Acquired 1,000 · Balance 6,308 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. Row 2 · 2026-02-09 · Sale · Disposed 20 · Balance 6,288 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. Row 3 · 2026-02-09 · Sale · Disposed 521 · Balance 5,767 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F2: Represents volume-weighted average price of sales of 521 shares of Company stock on February 9, 2026 at prices ranging from $776.05 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Row 4 · 2026-02-09 · Sale · Disposed 391 · Balance 5,376 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F3: Represents volume-weighted average price of sales of 391 shares of Company stock on February 9, 2026 at prices ranging from $777.33 to $777.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Row 5 · 2026-02-09 · Sale · Disposed 563 · Balance 4,813 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F4: Represents volume-weighted average price of sales of 563 shares of Company stock on February 9, 2026 at prices ranging from $778.00 to $778.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Row 6 · 2026-02-09 · Sale · Disposed 205 · Balance 4,608 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F5: Represents volume-weighted average price of sales of 205 shares of Company stock on February 9, 2026 at prices ranging from $779.19 to $779.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Row 7 · 2026-02-09 · Sale · Disposed 75 · Balance 4,533 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F6: Represents volume-weighted average price of sales of 75 shares of Company stock on February 9, 2026 at prices ranging from $780.03 to $780.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Row 8 · 2026-02-09 · Sale · Disposed 26 · Balance 4,507 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F7: Represents volume-weighted average price of sales of 26 shares of Company stock on February 9, 2026 at prices ranging from $781.18 to $781.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Row 9 · 2026-02-09 · Sale · Disposed 37 · Balance 4,470 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F8: Represents volume-weighted average price of sales of 37 shares of Company stock on February 9, 2026 at prices ranging from $782.22 to $782.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Row 10 · 2026-02-09 · Sale · Disposed 144 · Balance 4,326 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F9: Represents volume-weighted average price of sales of 144 shares of Company stock on February 9, 2026 at prices ranging from $783.17 to $783.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Row 11 · 2026-02-09 · Sale · Disposed 1 · Balance 4,325 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. Row 12 · 2026-02-09 · Sale · Disposed 53 · Balance 4,272 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F10: Represents volume-weighted average price of sales of 53 shares of Company stock on February 9, 2026 at prices ranging from $785.72 to $785.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $492.00 · Expires 2030-12-09 | Direct | 905 |
Reported balance
After 2026-02-09 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-02-09 · Exercise / conversion · Disposed 1,000 · Balance 905 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F11: The stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 31 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 31 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 179 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 179 |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025.
F2: Represents volume-weighted average price of sales of 521 shares of Company stock on February 9, 2026 at prices ranging from $776.05 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F3: Represents volume-weighted average price of sales of 391 shares of Company stock on February 9, 2026 at prices ranging from $777.33 to $777.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F4: Represents volume-weighted average price of sales of 563 shares of Company stock on February 9, 2026 at prices ranging from $778.00 to $778.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F5: Represents volume-weighted average price of sales of 205 shares of Company stock on February 9, 2026 at prices ranging from $779.19 to $779.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F6: Represents volume-weighted average price of sales of 75 shares of Company stock on February 9, 2026 at prices ranging from $780.03 to $780.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F7: Represents volume-weighted average price of sales of 26 shares of Company stock on February 9, 2026 at prices ranging from $781.18 to $781.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F8: Represents volume-weighted average price of sales of 37 shares of Company stock on February 9, 2026 at prices ranging from $782.22 to $782.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F9: Represents volume-weighted average price of sales of 144 shares of Company stock on February 9, 2026 at prices ranging from $783.17 to $783.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F10: Represents volume-weighted average price of sales of 53 shares of Company stock on February 9, 2026 at prices ranging from $785.72 to $785.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
F11: The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $492.00 | $0.00 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · derivative · entry 15 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 905 Underlying: Common Stock · 1,000 shares Expires 2030-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F11 · derivative.exercise_date: The stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 53 | $785.72 | $41,643.16 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 12 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,272 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F10 · price: Represents volume-weighted average price of sales of 53 shares of Company stock on February 9, 2026 at prices ranging from $785.72 to $785.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $784.66 | $784.66 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 11 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,325 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 144 | $783.23 | $112,785.12 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 10 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,326 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F9 · price: Represents volume-weighted average price of sales of 144 shares of Company stock on February 9, 2026 at prices ranging from $783.17 to $783.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 37 | $782.67 | $28,958.79 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 9 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,470 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F8 · price: Represents volume-weighted average price of sales of 37 shares of Company stock on February 9, 2026 at prices ranging from $782.22 to $782.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 26 | $781.37 | $20,315.62 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 8 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,507 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F7 · price: Represents volume-weighted average price of sales of 26 shares of Company stock on February 9, 2026 at prices ranging from $781.18 to $781.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 75 | $780.06 | $58,504.50 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 7 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,533 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F6 · price: Represents volume-weighted average price of sales of 75 shares of Company stock on February 9, 2026 at prices ranging from $780.03 to $780.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 205 | $779.56 | $159,809.80 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 6 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,608 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F5 · price: Represents volume-weighted average price of sales of 205 shares of Company stock on February 9, 2026 at prices ranging from $779.19 to $779.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 563 | $778.35 | $438,211.05 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 5 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,813 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F4 · price: Represents volume-weighted average price of sales of 563 shares of Company stock on February 9, 2026 at prices ranging from $778.00 to $778.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 391 | $777.51 | $304,006.41 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 4 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,376 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F3 · price: Represents volume-weighted average price of sales of 391 shares of Company stock on February 9, 2026 at prices ranging from $777.33 to $777.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 521 | $776.43 | $404,520.03 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 3 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,767 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F2 · price: Represents volume-weighted average price of sales of 521 shares of Company stock on February 9, 2026 at prices ranging from $776.05 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 20 | $775.95 | $15,519.00 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 2 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,288 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $492.00 | $492,000.00 |
DisclosureSEC source: 0002009236-26-000001 · edgardoc.xml · nonDerivative · entry 1 Pitofsky Jason · CIK 0002009236 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 22:38 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 989 | $712.94 | $705,097.66 |
DisclosureSEC source: 0002009236-25-000008 · edgardoc.xml · nonDerivative · entry 2 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,308 Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 22:38 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,261 | $0.00 Strike: $726.71 | $0.00 |
DisclosureSEC source: 0002009236-25-000008 · edgardoc.xml · derivative · entry 5 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,261 Underlying: Common Stock · 2,261 shares Expires 2035-12-05 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 22:38 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,064 | $0.00 | $0.00 |
DisclosureSEC source: 0002009236-25-000008 · edgardoc.xml · nonDerivative · entry 1 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,297 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 21:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 431 | $651.43 | $280,766.33 |
DisclosureSEC source: 0002009236-25-000006 · edgardoc.xml · nonDerivative · entry 1 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,233 Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 298 | $730.81 | $217,781.38 |
DisclosureSEC source: 0001968202-24-000140 · edgardoc.xml · nonDerivative · entry 1 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,664 Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 149 | $787.00 | $117,263.00 |
DisclosureSEC source: 0001883850-24-000051 · edgardoc.xml · nonDerivative · entry 2 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,962 Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,236 | $0.00 Strike: $771.64 | $0.00 |
DisclosureSEC source: 0001883850-24-000051 · edgardoc.xml · derivative · entry 6 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,236 Underlying: Common Stock · 3,236 shares Expires 2034-12-06 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 907 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000051 · edgardoc.xml · nonDerivative · entry 1 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,111 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028. Read SEC document |
| August 07, 2024 Filed Aug 7, 2024 20:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 487 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001883850-24-000043 · edgardoc.xml · derivative · entry 4 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 487 shares Expires 2029-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 07, 2024 Filed Aug 7, 2024 20:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 487 | $1,070.00 | $521,090.00 |
DisclosureSEC source: 0001883850-24-000043 · edgardoc.xml · nonDerivative · entry 2 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,204 Read SEC document |
| August 07, 2024 Filed Aug 7, 2024 20:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 487 | $372.46 | $181,388.02 |
DisclosureSEC source: 0001883850-24-000043 · edgardoc.xml · nonDerivative · entry 1 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 90 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000051 · edgardoc.xml · nonDerivative · entry 4 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 179 Read SEC document |
| April 04, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 89 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-24-000051 · edgardoc.xml · nonDerivative · entry 3 Pitofsky Jason · CIK 0002009236 · VP Controller 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 89 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.